Corvus Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $891.35M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | During market hours | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | – | $-0.15 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | During market hours | – | $-0.15 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | During market hours | – | $-0.12 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | During market hours | – | $-0.10 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | During market hours | – | $-0.13 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 25, 2025 | During market hours | – | $-0.18 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 6, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 19, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Nov 12, 2024, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| projected cash balance | at December 31, 2024 | $38.00M to $39.00M | New |
| net cash used in operating activities | full year 2024 | $25.00M to $26.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Corvus Pharmaceuticals filed with the SEC
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Provides Business Update and Reports Second
Results of operations · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Provides Business Update and Reports First
Results of operations · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Provides Business Update and Reports Fourth
Results of operations · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
Executive or director change · Other events · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K